Interferon beta 1a (IFN-beta1a)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3705
R7905
Nguyen (control exposed to Glatiramer), 2019 Pre-term (<37 weeks) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.80 [0.46;1.41] C
excluded (control group)
47/223   24/96 71 223
ref
S3707
R7911
Nguyen (control unexposed, sick), 2019 Pre-term (<37 weeks) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.74 [0.51;1.06] C 47/223   182/686 229 223
ref
S3709
R7919
Fragoso a (control exposed to Glatiramer), 2013 Prematurity (NOS) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 6.08 [0.64;57.61] C
excluded (control group)
4/29   1/39 5 29
ref
S3711
R7957
Fragoso a (control unexposed, sick), 2013 Prematurity (NOS) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 4.91 [1.03;23.37] C 4/29   3/95 7 29
ref
S3698
R7879
Weber-Schoendorfer (control exposed to Glatiramer), 2009 Preterm births at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 3.43 [0.38;31.22] C
excluded (control group)
5/40   1/25 6 40
ref
S3700
R7887
Weber-Schoendorfer (control unexposed, disease free), 2009 Preterm births at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 2.04 [0.78;5.34] C
excluded (control group)
5/40   90/1,377 95 40
ref
S3702
R7895
Weber-Schoendorfer (control unexposed, sick), 2009 Preterm births at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.84 [0.25;2.79] C 5/40   8/55 13 40
ref
Total 3 studies 1.16 [0.45;2.99] 249 292
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Nguyen (control unexposed, sick), 2019Nguyen, 2019 1 0.74[0.51; 1.06]22922349%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fragoso a (control unexposed, sick), 2013Fragoso a, 2013 2 4.91[1.03; 23.37]72922%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Weber-Schoendorfer (control unexposed, sick), 2009Weber-Schoendorfer, 2009 3 0.84[0.25; 2.79]134029%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 63% 1.16[0.45; 2.99]2492920.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: control unexposed, sick; 2: control unexposed, sick; 3: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.45; 2.99]24929263%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.16[0.45; 2.99]24929263%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 3 Tags Adjustment   - No  - No 1.16[0.45; 2.99]24929263%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 3 All studiesAll studies 1.16[0.45; 2.99]24929263%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3698, 3700, 3709, 3705

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.04[0.78; 5.34]9540 -NAWeber-Schoendorfer (control unexposed, disease free), 2009 1 unexposed, sick controlsunexposed, sick controls 1.16[0.45; 2.99]24929263%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.77[0.46; 6.87]8229253%NANguyen (control exposed to Glatiramer), 2019 Fragoso a (control exposed to Glatiramer), 2013 Weber-Schoendorfer (control exposed to Glatiramer), 2009 30.510.01.0